What type of study is this?

October 3, 2025BMC CancerOpen Access

Torso FDG-PET parameters as prognostic biomarkers for advanced non-small cell lung cancer patients undergoing first-line immunotherapy and chemotherapy

View Full Paper

Ask AI

Bookmark

Patients with lower metabolic tumor volume had significantly improved progression-free survival and overall survival.
Key metrics from FDG PET revealed significant associations with clinical outcomes, including progression-free survival and overall survival.
Higher metabolic tumor volume was linked to poorer performance status in patients with advanced non-small cell lung cancer.
Metabolic tumor volume emerged as an independent predictor of survival in patients undergoing first-line treatment with immunotherapy.

Authors

TOTakafumi ObataKagawa University TNTakashi NorikaneKagawa University YMYuri ManabeKagawa University

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Retrospective analysis identifies metabolic tumor volume as a key prognostic biomarker in non-small cell lung cancer, suggesting its relevance in treatment planning.

Cite This Study

Obata et al. (2025) studied this question.

synapsesocial.com/papers/68e02f2cf0e39f13e7fa1fc5 https://doi.org/10.1186/s12885-025-14873-8

View Full Paper

Ask AI

Bookmark

Implication

Retrospective analysis identifies metabolic tumor volume as a key prognostic biomarker in non-small cell lung cancer, suggesting its relevance in treatment planning.

Torso FDG-PET parameters as prognostic biomarkers for advanced non-small cell lung cancer patients undergoing first-line immunotherapy and chemotherapy

Key Points

Discussion

Implication

Cite This Study

Torso FDG-PET parameters as prognostic biomarkers for advanced non-small cell lung cancer patients undergoing first-line immunotherapy and chemotherapy

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider